Bifogade filer
Kurs
+1,19%
Likviditet
1,06 MSEK
Kalender
Est. tid* | ||
2026-02-06 | 08:30 | Bokslutskommuniké 2025 |
2025-10-24 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-07-11 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-04-10 | - | Kvartalsrapport 2025-Q1 |
2025-04-04 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2025-04-03 | - | Årsstämma |
2025-02-05 | - | Bokslutskommuniké 2024 |
2024-10-25 | - | Kvartalsrapport 2024-Q3 |
2024-07-12 | - | Kvartalsrapport 2024-Q2 |
2024-05-22 | - | Extra Bolagsstämma 2024 |
2024-04-24 | - | Kvartalsrapport 2024-Q1 |
2024-04-10 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2024-04-09 | - | Årsstämma |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-10-27 | - | Kvartalsrapport 2023-Q3 |
2023-07-14 | - | Kvartalsrapport 2023-Q2 |
2023-05-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2023-05-02 | - | Årsstämma |
2023-04-28 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-16 | - | Kvartalsrapport 2022-Q3 |
2022-07-15 | - | Kvartalsrapport 2022-Q2 |
2022-04-29 | - | Kvartalsrapport 2022-Q1 |
2022-04-05 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2022-04-04 | - | Årsstämma |
2022-02-11 | - | Bokslutskommuniké 2021 |
2021-10-29 | - | Kvartalsrapport 2021-Q3 |
2021-07-16 | - | Kvartalsrapport 2021-Q2 |
2021-05-11 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2021-05-10 | - | Årsstämma |
2021-04-29 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-07-17 | - | Kvartalsrapport 2020-Q2 |
2020-04-24 | - | Kvartalsrapport 2020-Q1 |
2020-04-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2020-04-02 | - | Årsstämma |
2020-03-10 | - | Extra Bolagsstämma 2020 |
2020-02-07 | - | Bokslutskommuniké 2019 |
2019-10-25 | - | Kvartalsrapport 2019-Q3 |
2019-07-19 | - | Kvartalsrapport 2019-Q2 |
2019-05-07 | - | Extra Bolagsstämma 2019 |
2019-04-26 | - | Kvartalsrapport 2019-Q1 |
2019-04-09 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2019-04-08 | - | Årsstämma |
2019-02-08 | - | Bokslutskommuniké 2018 |
2018-10-26 | - | Kvartalsrapport 2018-Q3 |
2018-07-20 | - | Kvartalsrapport 2018-Q2 |
2018-04-27 | - | Kvartalsrapport 2018-Q1 |
2018-04-10 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2018-04-09 | - | Årsstämma |
2018-02-23 | - | Bokslutskommuniké 2017 |
2017-11-10 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-23 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2017-05-22 | - | Årsstämma |
2017-05-15 | - | Kvartalsrapport 2017-Q1 |
2017-02-24 | - | Bokslutskommuniké 2016 |
2017-02-20 | - | Extra Bolagsstämma 2017 |
2016-11-04 | - | Kvartalsrapport 2016-Q3 |
2016-08-19 | - | Kvartalsrapport 2016-Q2 |
2016-05-25 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2016-05-24 | - | Årsstämma |
2016-05-17 | - | Kvartalsrapport 2016-Q1 |
2016-02-23 | - | Bokslutskommuniké 2015 |
2015-11-06 | - | Kvartalsrapport 2015-Q3 |
2015-08-21 | - | Kvartalsrapport 2015-Q2 |
2015-05-07 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2015-05-06 | - | Årsstämma |
2015-05-06 | - | Kvartalsrapport 2015-Q1 |
2015-02-20 | - | Bokslutskommuniké 2014 |
2014-11-07 | - | Kvartalsrapport 2014-Q3 |
2014-08-22 | - | Kvartalsrapport 2014-Q2 |
2014-06-04 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2014-06-03 | - | Årsstämma |
2014-05-09 | - | Kvartalsrapport 2014-Q1 |
2014-02-21 | - | Bokslutskommuniké 2013 |
2014-02-12 | - | Extra Bolagsstämma 2014 |
2013-11-06 | - | Kvartalsrapport 2013-Q3 |
2013-08-22 | - | Kvartalsrapport 2013-Q2 |
2013-05-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
2013-05-03 | - | Kvartalsrapport 2013-Q1 |
2013-05-02 | - | Årsstämma |
2013-04-03 | - | Extra Bolagsstämma 2013 |
2013-02-21 | - | Bokslutskommuniké 2012 |
2012-11-21 | - | Kvartalsrapport 2012-Q3 |
2012-08-22 | - | Kvartalsrapport 2012-Q2 |
2012-06-04 | - | Årsstämma |
2012-05-04 | - | Kvartalsrapport 2012-Q1 |
2012-02-21 | - | Bokslutskommuniké 2011 |
2011-11-21 | - | Kvartalsrapport 2011-Q3 |
2011-08-22 | - | Kvartalsrapport 2011-Q2 |
2011-07-20 | - | Split EPIS B 6:1 |
2011-06-30 | - | Årsstämma |
2011-05-21 | - | Kvartalsrapport 2011-Q1 |
2011-05-13 | - | Extra Bolagsstämma 2011 |
2011-05-02 | - | Kvartalsrapport 2011-Q1 |
2011-02-18 | - | Bokslutskommuniké 2010 |
2010-08-30 | - | Extra Bolagsstämma 2010 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Episurf Medical (Nasdaq: EPIS B) today announces that an article on the surgical technique for Episurf Medical's implant system for treatment for osteochondral defects in the ankle joint, Episealer® Talus, has been published in the scientific journal Foot & Ankle Clinics. The publication, with the title "Personalized Resurfacing for Osteochondral Lesions of the Talus", by F. G. Usuelli, MD, B. Efrima, MD and Prof. N. van Dijk, covers areas such as the etiology of typical ankle lesions and alternative treatment methodologies, in addition to providing a detailed review of the surgical technique for Episealer® Talus.
The authors state that osteochondral lesions of the talus (OLTs) are the most common cause of chronic deep ankle pain and that treating symptomatic OLTs can be challenging. The authors further conclude that they believe that the Episealer® Talus technique is proven effective, that they have had positive experiences from using the technique, and that the treatment alternative serves as a viable treatment option for OLTs and can serve as a bridge between biologics and conventional joint arthroplasty.
"This is a welcome addition to the library of scientific publications on the Episealer® technology. Over the years, surgeons have given us very positive feedback on the user-friendliness of our technology, and they have testified to the precision and accuracy of the surgical pre-planning, surgical drill guides, and implants. We are pleased to see this scientific paper being published, and that the lack of compromises on implant location, size, and shape is highlighted as true benefits of our patient-specific technology - which we fully agree with," says Pål Ryfors, CEO Episurf Medical.
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com